Richard J. Ablin

Corporate Officer/Principal presso Tetragenex Pharmaceuticals, Inc.

Consumer Services

Health Technology

Profilo

Richard J.
Ablin is currently the Director of Tetracycline Evaluation at Tetragenex Pharmaceuticals, Inc. He was previously the Director and Research Associate Professor at The State University of New York from 1983 to 1989.
Ablin received his doctorate degree from the State University of New York at Buffalo in 1967.

Posizioni attive di Richard J. Ablin

Società	Posizione	Inizio
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Corporate Officer/Principal	05/02/2010

Tutte le posizioni attive di Richard J. Ablin

Precedenti posizioni note di Richard J. Ablin

Società	Posizione	Fine
The State University of New York	Direttore/Membro del Consiglio	01/01/1989

Vedi nel dettaglio l'esperienza di Richard J. Ablin

Formazione di Richard J. Ablin

State University of New York at Buffalo

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Richard J. Ablin

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Health Technology